The next evolution in gene therapy
StrideBio’s internal pipeline is focused on developing innovative gene therapies for inherited cardiovascular diseases. We have partnered with leading biopharmaceutical companies to develop gene therapies for rare neurological diseases.
In November 2019, StrideBio and Sarepta Therapeutics, Inc. announced a collaboration and license agreement to develop in vivo AAV-based therapies for up to eight central nervous system and neuromuscular targets. Under the agreement, Sarepta was granted an exclusive license on selected targets to leverage StrideBio’s novel, structure-driven capsid technology, intended to enhance specific tropism to tissues of interest and evade neutralizing antibodies. LEARN MORE
In March 2019, StrideBio and Takeda Pharmaceutical Company Limited signed a collaboration and license agreement to develop in vivo AAV-based therapies for Friedreich’s Ataxia and two additional undisclosed targets. LEARN MORE
In April 2017, StrideBio announced it had entered a strategic collaboration with CRISPR Therapeutics to generate engineered AAV capsids with improved properties for in vivo gene editing programs. StrideBio and CRISPR expanded the successful collaboration in February 2019 to include additional, undisclosed gene editing applications. LEARN MORE